BiotechTube

Imatinib Mesylate and Nilotinib

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Graft Versus Host Disease

Conditions

Graft Versus Host Disease

Trial Timeline

Dec 24, 2012 → Jul 26, 2017

NCT ID
NCT02891395

About Imatinib Mesylate and Nilotinib

Imatinib Mesylate and Nilotinib is a phase 2 stage product being developed by Novartis for Graft Versus Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02891395. Target conditions include Graft Versus Host Disease.

What happened to similar drugs?

20 of 20 similar drugs in Graft Versus Host Disease were approved

Approved (20) Terminated (1) Active (0)
✅Prograf + Methotrexate + CyclosporineAstellas PharmaApproved
✅tacrolimusAstellas PharmaApproved
✅azathioprine + sirolimusAstellas PharmaApproved
✅Aspirin + TicagrelorAstraZenecaApproved
✅SugammadexMerckApproved
✅RuxolitinibNovartisApproved
✅CyclosporineNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02891395Phase 2Completed

Competing Products

20 competing products in Graft Versus Host Disease

See all competitors
ProductCompanyStageHype Score
Prograf + Methotrexate + CyclosporineAstellas PharmaApproved
43
AlefaceptAstellas PharmaPhase 2
27
tacrolimusAstellas PharmaApproved
43
Tacrolimus + TacrolimusAstellas PharmaPre-clinical
26
azathioprine + sirolimusAstellas PharmaApproved
43
Itolizumab + EQ001 PlaceboBioconPhase 3
32
EQ001 + EQ001 PlaceboBioconPhase 1/2
32
SHR0302Jiangsu Hengrui MedicinePhase 1
29
AcalabrutinibAstraZenecaPhase 2
39
Aspirin + TicagrelorAstraZenecaApproved
43
SugammadexMerckApproved
43
Efprezimod alfa + Methotrexate + Tacrolimus + PlaceboMerckPhase 2
35
RuxolitinibNovartisApproved
50
Prednisone + Jakavi(ruxolitinib) + PrednisoneNovartisPhase 2
42
PredEverNovartisPhase 2
35
Lifitegrast 5% Ophthalmic Solution + PlaceboNovartisPhase 1
29
CyclosporineNovartisApproved
39
Everolimus + Tacrolimus + Mycophenolic acidNovartisApproved
39
1 + 2NovartisApproved
43
Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte GlobulinNovartisApproved
43